[The efficacy of diclonate P in psoriatic arthritis].
Ten patients with significant psoriatic arthritis (PA) were placed under observation for the efficacy of diclonate P (sodium diclofenac) manufactured by Pliva Company (Croatia), administered in the daily dose 200 mg. Diclonate P was demonstrated to produce a high clinical effect. Nine patients preferred it to other nonsteroidal antiinflammatory drugs taken before (ortophen, metindol, flugalin). Out of 12 subjective and objective characteristics used for estimation of the drug efficacy, 10 improved, while 7 of them improved significantly. Transient gastralgias were only recorded in one female patient. It is concluded that diclonate P possesses a significant antiinflammatory and analgesic efficacy in PA and has a beneficial effect on the articular syndrome and spinal symptoms. It is tolerated well and has no adverse action on psoriasis.
Burdeĭnyĭ
A P
AP
D000328:Adult; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000453:epidemiology; D002908:Chronic Disease; D004008:Diclofenac / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D018709:Statistics, Nonparametric; D013997:Time Factors
D004008:Diclofenac
Effektivnost' diklonata P pri psoriaticheskom artrite.